Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence study of MTD201 (Q-Octreotide)

Next Previous
X
Search
Trial Profile

Bioequivalence study of MTD201 (Q-Octreotide)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Malignant carcinoid syndrome
  • Focus First in man; Pharmacokinetics; Proof of concept
  • Sponsors Biodexa Pharmaceuticals

    • Most Recent Events

    • 16 May 2023 According to Biodexa Pharmaceuticals, 20-F filing, Midatech has changed its name to Biodexa Pharmaceuticals
    • 08 Oct 2019 event According to a Midatech media release, top line results expected by the end of 2019 or early in 2020.
    • 08 Oct 2019 According to a Midatech media release, the first cohort , 14 out of 28 subjects, received one dose of Sandostatin 100 microgram/1 ml solution for injection on 5 October 2019, which was followed yesterday by a 30mg injection of MTD201 via either the subcutaneous or intramuscular route. he remaining 14 subjects will undergo the same procedures later this week to complete the dosing phase of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top